Article Information
History
- September 5, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Zhiliang Hu1,2,†,
- Bilin Tao2,†,
- Zhongqi Li2,†,
- Yan Song1,
- Changhua Yi1,
- Junwei Li1,
- Meng Zhu2,
- Yongxiang Yi1,*,
- Peng Huang2,* and
- Jianming Wang2,*
- 1Nanjing Public Health Medical Center, the Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003 China
- 2Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, 211166 China
- ↵*Corresponding authors: Yongxiang Yi.
Nanjing Public Health Medical Center, the Second Hospital of Nanjing, Nanjing University of Chinese Medicine, 1-1 Zhongfu Rd., Nanjing, 210003, China. Telephone: 025-83626203. Email: ian0126{at}126.com, Peng Huang.
Nanjing Medical University, 101 Longmian Ave., Nanjing, 211166, China. Telephone: 025-86868291. Email: huangpeng{at}njmu.edu.cn, Jianming Wang.
Nanjing Medical University, 101 Longmian Ave., Nanjing, 211166, China. Telephone: 025-86868414. Email: jmwang{at}njmu.edu.cn
↵† These authors have contributed equally to this work
Posted September 05, 2021.
Effectiveness of inactive COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China
